Planet Fitness (PLNT) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.84%. A quarter ago, it was expected that this fitness center operator would post earnings of $0.62 per share when it actually produced earnings of $0.70, delivering a surprise of 12.90%.Over the last four quarter ...

Core Insights - Sapiens (SPNS) reported quarterly earnings of $0.37 per share, exceeding the Zacks Consensus Estimate of $0.35 per share, and showing a slight increase from $0.36 per share a year ago [1][2] - The company posted revenues of $136.11 million for the quarter ended March 2025, which was below the Zacks Consensus Estimate by 0.30%, and an increase from $134.25 million year-over-year [3] - Sapiens has surpassed consensus EPS estimates three times in the last four quarters, but has not beaten revenue estimates during the same period [2][3] Financial Performance - The earnings surprise for the recent quarter was 5.71%, and the previous quarter's surprise was 2.78% [2] - The current consensus EPS estimate for the upcoming quarter is $0.37, with expected revenues of $139 million, and for the current fiscal year, the EPS estimate is $1.46 on revenues of $555.81 million [8] Market Position - Sapiens shares have increased by approximately 8.2% since the beginning of the year, contrasting with a decline of -4.3% in the S&P 500 [4] - The Zacks Industry Rank places the Computer - Software sector in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [9] Future Outlook - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [4][5] - The current Zacks Rank for Sapiens is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [7]

Core Viewpoint - Enhabit (EHAB) reported quarterly earnings of $0.10 per share, exceeding the Zacks Consensus Estimate of $0.07 per share, marking a 42.86% earnings surprise compared to the previous year's earnings of $0.07 per share [1] Financial Performance - Enhabit posted revenues of $259.9 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.56% and down from $262.4 million year-over-year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [2] Stock Performance - Enhabit shares have increased by approximately 2.9% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $267.14 million, and for the current fiscal year, it is $0.37 on revenues of $1.07 billion [7] - The estimate revisions trend for Enhabit is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical Services industry, to which Enhabit belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Financial Performance - Orion reported quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.53 per share, and down from $0.52 per share a year ago, representing an earnings surprise of -58.49% [1] - The company posted revenues of $477.7 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 1.69%, and down from $502.9 million year-over-year [2] - Over the last four quarters, Orion has surpassed consensus EPS estimates only once and has not beaten consensus revenue estimates during the same period [2] Stock Performance - Orion shares have declined approximately 27.4% since the beginning of the year, compared to a decline of -4.7% for the S&P 500 [3] - The current Zacks Rank for Orion is 4 (Sell), indicating expectations for the stock to underperform the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.43 on revenues of $477.53 million, and for the current fiscal year, it is $1.60 on revenues of $1.86 billion [7] - The trend for estimate revisions ahead of the earnings release was unfavorable, which may impact future stock performance [6] Industry Context - The Chemical - Specialty industry, to which Orion belongs, is currently ranked in the bottom 44% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Another company in the same industry, CSW Industrials, is expected to report quarterly earnings of $2.23 per share, reflecting a year-over-year change of +9.3% [9]

Liberty Media Corporation - Liberty Formula One Series C (FWONK) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.18 per share. This compares to earnings of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 127.78%. A quarter ago, it was expected that this company would post earnings of $0.46 per share when it actually produced a loss of $1.03, delivering a surprise ...

Core Viewpoint - Phibro Animal Health (PAHC) reported quarterly earnings of $0.63 per share, exceeding the Zacks Consensus Estimate of $0.52 per share, and showing significant growth from $0.31 per share a year ago [1][2]. Financial Performance - The earnings surprise for the quarter was 21.15%, with the company previously expected to earn $0.42 per share but actually earning $0.54, resulting in a surprise of 28.57% [2]. - Phibro's revenues for the quarter were $347.8 million, slightly missing the Zacks Consensus Estimate by 0.78%, compared to $263.2 million in the same quarter last year [3]. - Over the last four quarters, the company has surpassed consensus EPS estimates four times and topped revenue estimates twice [2][3]. Stock Performance - Phibro shares have declined approximately 9.3% since the beginning of the year, while the S&P 500 has decreased by 4.7% [4]. - The current Zacks Rank for Phibro is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.53, with expected revenues of $355.98 million, and for the current fiscal year, the estimate is $1.94 on $1.28 billion in revenues [8]. - The outlook for the Medical - Products industry, to which Phibro belongs, is currently in the bottom 28% of over 250 Zacks industries, which may impact stock performance [9].

Coeur Mining (CDE) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items. While Coeur Mining has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings ou ...

Core Insights - Evolus, Inc. reported a quarterly loss of $0.18 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, marking an earnings surprise of -80% [1] - The company's revenues for the quarter ended March 2025 were $68.52 million, missing the Zacks Consensus Estimate by 4.83%, but showing an increase from $59.33 million year-over-year [2] - Evolus has not surpassed consensus EPS estimates over the last four quarters and has only topped revenue estimates once in that same period [2] Company Performance - Evolus shares have increased by approximately 5.2% since the beginning of the year, contrasting with a -4.7% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $82.86 million, and for the current fiscal year, it is -$0.01 on revenues of $351.43 million [7] Earnings Outlook - The estimate revisions trend for Evolus is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] - The outlook for the Medical - Products industry, to which Evolus belongs, is in the bottom 28% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Cardlytics (CDLX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 22.22%. A quarter ago, it was expected that this company would post a loss of $0.24 per share when it actually produced break-even earnings, delivering a surprise of 100%.Over the last four quarters, the company has surpassed c ...

Smith Micro Software, Inc. (SMSI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -45.45%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.11, delivering no surprise.Over the last four quarters, the company has surpa ...